Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139808 | 0.89 | GRM5 (0.69) | LMNATSHRHTTALDH1A1MEN1 | |
| SCHEMBL4139816 | 0.89 | GRM5 (0.69) | LMNATSHRHTTALDH1A1MEN1 | |
| SCHEMBL2030060 | 0.85 | TSHR (0.72) | LMNATSHRHTTALDH1A1MEN1 | |
| SCHEMBL2024913 | 0.84 | TSHR (0.73) | LMNATSHRHTTALDH1A1MEN1 | |
| SCHEMBL2026741 | 0.84 | TSHR (0.64) | LMNATSHRHTTALDH1A1MEN1 | |
| SCHEMBL2030079 | 0.84 | RAB9A (0.61) | LMNATSHRHTTALDH1A1MEN1 | |
| SCHEMBL1653518 | 0.83 | TUBB4A (0.60) | LMNATSHR | |
| SCHEMBL12580577 | 0.83 | GRM5 (0.66) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL390646 | 0.82 | GPR119 (0.67) | LMNATSHRHTT | |
| SCHEMBL2026830 | 0.82 | TSHR (0.68) | LMNATSHRHTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | claimed |
| CN-116178361-A | Preparation of piperidine bisoxadiazole and piperidine amino thiazole substituted antitumor curcumenol derivatives and application thereof in antitumor | 华东理工大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| WO-2008003861-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2008-01-10 | — | — | WO | disclosed |
| WO-2000020414-A9 | PIPERIDYLOXADIAZOLES AS DOPAMINE RECEPTOR ANTAGONISTS | COMBICHEM INC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6107313-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | COMBICHEM, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000020414-A1 | PIPERIDYLOXADIAZOLES AS DOPAMINE RECEPTOR ANTAGONISTS | COMBICHEM, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | LMNA 4210/4885TSHR 222/4885HTT 3646/4885 |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | LMNA 1439/4885TSHR 2305/4885HTT 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.